Exertional Heat Illness
0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Initial TherapeuticsCA - South SF
2 programsCore temperature monitoringN/A
Heat Tolerance AssessmentN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Initial TherapeuticsHeat Tolerance Assessment
Defence TherapeuticsCore temperature monitoring
Clinical Trials (2)
Total enrollment: 878 patients across 2 trials
Comparing Exertional Heat Illness Risk Factors Between Patients and Controls
Start: Feb 2022Est. completion: Mar 202395 patients
N/ACompleted
Risk Factors for Exertional Heat Illness
Start: Jun 2021Est. completion: Jul 2025783 patients
N/AActive Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.